Results 251 to 260 of about 693,447 (371)

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

open access: yesAdvanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin   +6 more
wiley   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

open access: yesAdvanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin   +14 more
wiley   +1 more source

Targeted Inhibition of CD74+ Macrophages by Luteolin via CEBPB/P65 Signaling Ameliorates Osteoarthritis Progression

open access: yesAdvanced Science, EarlyView.
This study identifies CD74⁺ macrophages as key drivers of synovial inflammation in osteoarthritis (OA). The flavonoid luteolin is predicted to inhibit this pathway by blocking Nuclear Factor Kappa‐light‐chain‐enhancer of Activated B cells (NF‐κB) signaling. To enhance delivery, a targeted nanoplatform (MDSPL) is developed.
Rui Peng   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy